Rezolute RZLT 深 沪
已收盘 07-02 16:00:00 美东时间
4.91
-0.040
-0.81%
华盛通- 最 高5.06
- 今 开4.99
- 成交量 279.48万股
- 最 低 4.84
- 昨 收 4.95
- 总市值 4.73亿
- 52周最高 11.4565
- 市盈率 静 --
- 换手率 2.90%
- 52周最低 1.07
- 委 比 85.57%
- 总股本 9629.23万
- 历史最高 21.11
- 量 比 0.91
- 振 幅 4.44%
- 历史最低 0.72
- 每 手 1
- 风险率 2.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rezolute Highlights ENDO Data On Congenital HI Outcomes And Tumor HI Case Series Supporting Ersodetug Program
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenital HI and a case series from its Expanded Access Program (EAP) in tumor HI REDWOOD CITY, Calif., June...
06-17 19:15
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Guggenheim Maintains Buy on Rezolute, Raises Price Target to $11
Guggenheim analyst Debjit Chattopadhyay maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $6 to $11.
06-15 23:12
美股牛股 | 黄仁勋概念股又+1！凭AI电源技术切入“达链”，纳微半导体暴涨超19%；MiniMed Group大涨近16%
黄仁勋概念股又+1！凭AI电源技术切入“达链”，纳微半导体暴涨超19%；季度销售额超预期！MiniMed Group大涨近16%>>
06-04 18:56
美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday
Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELYB, NN, BVC, MX, ECX, DRTS, RZLT, SYRE, TGTX.
06-03 23:19
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
Rezolute rises after late-stage trial update
Rezolute (RZLT) shares traded higher on Tuesday after the company announced an update from a late-stage trial for its lead candidate, ersodetug in tumor hyperinsulinism, a rare disease characterized b...
06-03 00:24
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $5 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $5 price target.
06-02 22:23
Rezolute Reports Mid-Study Results for Rare Hypoglycemia Treatment
Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today
06-02 19:03
